Search results for "Acute myeloid leukemia"

showing 10 items of 35 documents

Bacitracin and Rutin Regulate Tissue Factor Production in Inflammatory Monocytes and Acute Myeloid Leukemia Blasts

2021

Simple Summary Aberrant tissue factor (TF) expression by transformed myeloblasts and inflammatory monocytes contributes to coagulation activation in acute myeloid leukemia (AML). TF procoagulant activity (PCA) is regulated by protein disulfide isomerase (PDI), an oxidoreductase with chaperone activity, but its specific role in AML-associated TF biology is unclear. Here, we provide novel mechanistic insights into this interrelation. We show that bacitracin and rutin, two pan-inhibitors of the PDI family, prevent lipopolysaccharide (LPS)-induced monocyte TF production under inflammatory conditions and constitutive TF expression by THP1 cells and AML blasts, thus exerting promising anticoagula…

0301 basic medicineCancer ResearchMyeloidDaunorubicinacute myeloid leukemia030204 cardiovascular system & hematologyPeripheral blood mononuclear cellArticleFlow cytometry03 medical and health sciencesTissue factor0302 clinical medicineDownregulation and upregulationhemic and lymphatic diseasesmedicinecoagulationProtein disulfide-isomeraseRC254-282medicine.diagnostic_testChemistryrutinNeoplasms. Tumors. Oncology. Including cancer and carcinogensMyeloid leukemiatissue factorprotein disulfide isomeraseMolecular biology030104 developmental biologymedicine.anatomical_structureOncologyinflammationtissue factor; protein disulfide isomerase; acute myeloid leukemia; coagulation; inflammation; rutin; monocytesmonocytesmedicine.drugCancers
researchProduct

Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling

2016

Clinical cohorts with time-to-event endpoints are increasingly characterized by measurements of a number of single nucleotide polymorphisms that is by a magnitude larger than the number of measurements typically considered at the gene level. At the same time, the size of clinical cohorts often is still limited, calling for novel analysis strategies for identifying potentially prognostic SNPs that can help to better characterize disease processes. We propose such a strategy, drawing on univariate testing ideas from epidemiological case-controls studies on the one hand, and multivariable regression techniques as developed for gene expression data on the other hand. In particular, we focus on …

0301 basic medicineMultivariate analysisMicroarraysTest StatisticsGene Expressionlcsh:MedicineBioinformatics01 natural sciencesHematologic Cancers and Related DisordersCohort Studies010104 statistics & probabilityMathematical and Statistical TechniquesResamplingMedicine and Health Scienceslcsh:ScienceStatistical DataUnivariate analysisMultidisciplinarySimulation and ModelingMultivariable calculusRegression analysisHematologyMyeloid LeukemiaPrognosisRegressionBioassays and Physiological AnalysisOncologyResearch DesignPhysical SciencesStatistics (Mathematics)Research ArticleAcute Myeloid LeukemiaPermutationSingle-nucleotide polymorphismComputational biologyBiologyResearch and Analysis MethodsPolymorphism Single Nucleotide03 medical and health sciencesLeukemiasGeneticsHumansStatistical Methods0101 mathematicsDiscrete Mathematicslcsh:RUnivariateCancers and NeoplasmsBiology and Life SciencesModels Theoretical030104 developmental biologyCombinatoricsCase-Control StudiesMultivariate Analysislcsh:QMathematicsPLOS ONE
researchProduct

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

2018

© 2018 by the authors.

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyNPM1PTK2acute myeloid leukemialcsh:RC254-282Article03 medical and health sciences0302 clinical medicinePTK2BLYNInternal medicinehemic and lymphatic diseasesmedicineLYNprognostic factorPrognostic factorintermediate-riskPTK2BAcute myeloid leukemiaPTK2business.industryMyeloid leukemialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisCohortIntermediate-riskbusinessTyrosine kinaseProto-oncogene tyrosine-protein kinase SrcCancers
researchProduct

Immunoistochemical expression of PD-1 and PD-L1 in bone marrow biopsies of patients with acute myeloid leukemia

2020

Background. Haematological and non-haematological malignancies are able to escape the host immune by the capacity to hijack the immune check-points. Several immune check-point molecules are known, such as T cell immunoglobulin mucin-3 (TIM-3), cytotoxic T-cell antigen-4 (CTLA-4), programmed death-1 (PD-1) with its ligand PD-L1 and others.1 The function of these immune check-points is to prevent the damage resulting from an excessive activation of the immune response in the setting of chronic antigenic stimulation, thus leading to autoimmune phenomena, as proved in knock-out mice models. PD-1 is normally present on activated T lymphocytes membrane, acting as a negative costimulatory receptor…

0301 basic medicinemedicine.medical_treatmentvirusesanimal diseaseschemical and pharmacologic phenomena03 medical and health sciences0302 clinical medicinePD-L1Medicinebiologybusiness.industrylcsh:RC633-647.5Myeloid leukemiaHematologyImmunotherapylcsh:Diseases of the blood and blood-forming organsAcute myeloid leukemia Immune check-point blockade Immunotherapy PD-1 PD-L1biochemical phenomena metabolism and nutritionacute myeloid leukemia; immune check-point blockade; PD-1; PD-L1; immunotherapy030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer researchbiology.proteinbacteriaBone marrowbusinessHematology Reports
researchProduct

NUOVI AGENTI TERAPEUTICI PER IL TRATTAMENTO DI PATOLOGIE EMATOLOGICHE

2019

La presente invenzione si riferisce al campo di nuove molecole tetracicliche, aventi un sistema tetraciclico, e loro impiego come medicamenti di patologie ematologiche in particolare per il trattamento della leucemia mieloide acuta (AML) in pazienti emizigoti FLT3/ITD resistenti alle terapie convenzionali.

2H-Imidazo [2'1':23][13]thiazolo[45-e]isoindol-8-yl)phenyl]ureas Acute myeloid leukemia (AML) Internal tandem duplication (ITD) FMS-like tyrosine kinase 3 (FLT3) FLT3/ITDSettore CHIM/08 - Chimica Farmaceutica
researchProduct

NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF HAEMATOLOGICAL PATHOLOGIES

2021

2H-Imidazo [2'1':23][13]thiazolo[45-e]isoindol-8-yl-phenylureas Acute myeloid leukemia (AML) Internal tandem duplication (ITD) FMS-like tyrosine kinase 3 (FLT3) FLT3/ITD
researchProduct

Antitumor Mechanism of the Essential Oils from Two Succulent Plants in Multidrug Resistance Leukemia Cell

2019

Drug resistance remains a major challenge in the treatment of cancer. The multiplicity of the drug resistance determinants raises the question about the optimal strategies to deal with them. Essential oils showed to inhibit the growth of different tumor cell types. Essential oils contain several chemical classes of compounds whose heterogeneity of active moieties can help prevent the development of drug resistance. In the present paper, we analyzed, by gas chromatography-mass spectrometry the chemical composition of the essential oil of the leaves of Kalanchoe beharensis obtained by hydrodistillation and compared the chemical composition of its essential oil with that of Cyphostemma juttae.…

<i>Kalanchoe beharensis</i>Celllcsh:Medicinelcsh:RS1-441Pharmaceutical ScienceKalanchoe beharensiDrug resistanceArticleessential oilNF-κBlaw.inventionlcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineKalanchoe beharensislawmultidrug resistanceCyphostemma juttaeDrug DiscoverymedicineNF-kappaBSettore BIO/15 - Biologia FarmaceuticaEssential oilacute myeloid leukemia cell030304 developmental biology0303 health sciences<i>Cyphostemma juttae</i>biologylcsh:RMyeloid leukemiaCyphostemma juttaebiology.organism_classificationmedicine.diseaseMultiple drug resistanceLeukemiamedicine.anatomical_structureBiochemistry030220 oncology & carcinogenesisSettore BIO/03 - Botanica Ambientale E ApplicataSettore BIO/14 - FarmacologiaMolecular MedicineKalanchoe beharensisPharmaceuticals
researchProduct

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target

2018

Blastic Plasmacytoid Dendritic Cell Neoplasm is a rare and aggressive hematological malignancy currently lacking an effective therapy. To possibly identify genetic alterations useful for a new treatment design, we analyzed by whole-exome sequencing fourteen Blastic Plasmacytoid Dendritic Cell Neoplasm patients and the patient-derived CAL-1 cell line. The functional enrichment analysis of mutational data reported the epigenetic regulatory program as the most significantly undermined (P&lt;.0001). In particular, twenty-five epigenetic-modifiers were found mutated (e.g., ASXL1, TET2, SUZ12, ARID1A, PHF2, CHD8); ASXL1 was the most frequently affected (28.6% of cases). To evaluate the impact of …

Acute Myeloid LeukemiaBlastic plasmacytoid dendritic cell neoplasm epigenetic mutationsSkin NeoplasmsAzacitidineDecitabinePlasmacytoid dendritic cellGene mutationBiologyDecitabineBPDCNArticleEpigenesis Genetic03 medical and health sciences0302 clinical medicineHistone methylation5’-Azacytidine; Acute Myeloid Leukemia; BPDCN; Decitabine; WESmedicineHumansEpigeneticsExome sequencingRegulation of gene expressionMyeloproliferative DisordersDendritic CellsGenomicsHematology5 -AzacytidineMyeloid Neoplasms5’-AzacytidineCancer researchWES030215 immunologymedicine.drugHaematologica
researchProduct

Surface Marker Analysis by Monoclonal Antibodies: A Valuable Technique in Childhood Acute Myeloid Leukemia

1987

A considerable number of monoclonal antibodies (MoAbs) with myeloid activity have been described during the last few years (summarized in [1]). These MoAbs have been applied to the study of normal myeloid differentiation, as well as to the surface marker analysis of acute myeloid leukemia (AML) [2–6]. Although there is a strong tendency for morphological differentiation to correspond to surface antigen differentiation of malignant myeloid cells [2, 3], a recent report has failed to correlate the FAB classification system with immunologic categories of AML [6].

Acute leukemiaMyeloidAcute myeloblastic leukemiamedicine.drug_classbusiness.industryChildhood Acute Myeloid LeukemiaMyeloid leukemiamedicine.diseaseMonoclonal antibodymedicine.anatomical_structureAntigenhemic and lymphatic diseasesImmunologySurface markermedicinebusiness
researchProduct

Burkholderia cepacia septicemia in a patient with acute myeloid leukemia in postchemotherapy bone marrow aplasia

2013

The patients with hematologic malignancies are predisposed to develop infections with unusual bacteria, like Burkholderia cepacia, which is frequently resistant to many antibiotics and antiseptics. We present the case of a female patient with acute myeloid leukemia type 2 on the background of myelodysplastic syndrome, from whom Burkholderia cepacia was isolated in blood culture, after the 2(nd) cycle of induction. She was sensitive to ceftazidime, but its eradication was not easy. Five other patients were contaminated with this bacteria, but all of them had favourable evolution. The case is discussed in the context of those similar in literature.

Acute myeloid leukemiabiologymedicine.diagnostic_testbusiness.industrymedicine.drug_classAntibioticsMyeloid leukemiaCeftazidimeContext (language use)Case ReportGeneral MedicineBone Marrow AplasiaBurkholderia cepaciabiology.organism_classificationCeftazidimeMicrobiologyCotrimoxazoleBurkholderiaImmunologyMedicinebacteriaBlood culturebusinessBacteriamedicine.drugPakistan Journal of Medical Sciences
researchProduct